Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON25676
NL-OMON25676
Not yet recruiting
Not Applicable

Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.

Erasmus MC0 sites390 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSolid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.
Sponsor
Erasmus MC
Enrollment
390
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Erasmus MC

Eligibility Criteria

Inclusion Criteria

  • •Age \=18 years;
  • •\- Able and willing to give written informed consent;
  • •\- Planned treatment with Nivolumab or Pembrolizumab monotherapy (in case of Nivolumab with or without prior
  • •treatment with Nivolumab/Ipilimumab) for any EMA approved indication and with any dose;
  • •\- Adequate Dutch language proficiency (at least proficiency level C1\)
  • •\- At least 3 prior cycles of Nivolumab or Pembrolizumab therapy
  • •\- At least 4 remaining cycles of Nivolumab or Pembrolizumab monotherapy after inclusion in the study.

Exclusion Criteria

  • •\- Prior infusion related reactions to Nivolumab or Pembrolizumab (any grade).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-000058-24-NLErasmus MC Cancer Institute390
Recruiting
Phase 4
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.NSCLC and head and neck cancerrenal-cell cancerSolid or hematological tumors for which Nivolumab or Pembrolizumab monotherapy have an EMA approved indication. This includes (but is not limited to) melanomaVarious forms of cancer for which Nivolumab or Pembrolizumab monotherapy are prescribed as treatment10027656
NL-OMON54425Erasmus MC, Universitair Medisch Centrum Rotterdam390
Not yet recruiting
Not Applicable
Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.
JPRN-UMIN000050723Kobe University200
Completed
Not Applicable
Combination therapy of immuno checkpoint inhibitors and radiosensitization treatment for metastatic melanoma
JPRN-UMIN000026925Kochi University, Kochi Medical School5
Active, not recruiting
Phase 1
Pre-operative immunotherapy in early-stage colon cancers
EUCTR2016-002940-17-NLAntoni van Leeuwenhoek155